COVID-19 in Patients with Pulmonary Hypertension : A National Prospective Cohort Study
Rationale: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with pulmonary endothelial dysfunction. There are limited data available on the outcomes of coronavirus disease (COVID-19) in patients with pulmonary hypertension (PH), a disease characterized by pulmonary endothelial dysfunction. Objectives: To describe characteristics and outcomes of patients with precapillary PH and COVID-19. Methods: We prospectively collected characteristics, management, and outcomes of adult patients with precapillary PH in the French PH network who had COVID-19 between February 1, 2020, and April 30, 2021. Clinical, functional, and hemodynamic characteristics of PH before COVID-19 were collected from the French PH registry. Measurements and Main Results: A total of 211 patients with PH (including 123 with pulmonary arterial hypertension, 47 with chronic thromboembolic PH, and 41 with other types of PH) experienced COVID-19, and 40.3% of them were outpatients, 32.2% were hospitalized in a conventional ward, and 27.5% were in an ICU. Among hospitalized patients (n = 126), 54.0% received corticosteroids, 37.3% high-flow oxygen, and 11.1% invasive ventilation. Right ventricular and acute renal failure occurred in 30.2% and 19.8% of patients, respectively. Fifty-two patients (all hospitalized) died from COVID-19. Overall mortality was 24.6% (95% CI [confidence interval], 18.8-30.5) and in-hospital mortality 41.3% (95% CI, 32.7-49.9). Nonsurvivors were significantly older, more frequently male and suffering comorbidities (diabetes, chronic respiratory diseases, systemic hypertension, chronic cardiac diseases, and/or chronic renal failure), and had more severe PH at their most recent evaluation preceding COVID-19 diagnosis (in terms of functional class and 6-minute-walk distance; all P < 0.05). Use of pulmonary arterial hypertension therapy was similar between survivors and nonsurvivors. Conclusions: COVID-19 in patients with precapillary PH was associated with a high in-hospital mortality. The typical risk factors for severe COVID-19 and severity of PH were associated with mortality in this population.
| Errataetall: |
CommentIn: Am J Respir Crit Care Med. 2022 Sep 1;206(5):526-528. - PMID 35584345 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:206 |
|---|---|
| Enthalten in: |
American journal of respiratory and critical care medicine - 206(2022), 5 vom: 01. Sept., Seite 573-583 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Montani, David [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 08.09.2022 Date Revised 22.02.2023 published: Print CommentIn: Am J Respir Crit Care Med. 2022 Sep 1;206(5):526-528. - PMID 35584345 Citation Status MEDLINE |
|---|
| doi: |
10.1164/rccm.202112-2761OC |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340779977 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340779977 | ||
| 003 | DE-627 | ||
| 005 | 20231226010236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1164/rccm.202112-2761OC |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM340779977 | ||
| 035 | |a (NLM)35549842 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Montani, David |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 in Patients with Pulmonary Hypertension |b A National Prospective Cohort Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2022 | ||
| 500 | |a Date Revised 22.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Am J Respir Crit Care Med. 2022 Sep 1;206(5):526-528. - PMID 35584345 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Rationale: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with pulmonary endothelial dysfunction. There are limited data available on the outcomes of coronavirus disease (COVID-19) in patients with pulmonary hypertension (PH), a disease characterized by pulmonary endothelial dysfunction. Objectives: To describe characteristics and outcomes of patients with precapillary PH and COVID-19. Methods: We prospectively collected characteristics, management, and outcomes of adult patients with precapillary PH in the French PH network who had COVID-19 between February 1, 2020, and April 30, 2021. Clinical, functional, and hemodynamic characteristics of PH before COVID-19 were collected from the French PH registry. Measurements and Main Results: A total of 211 patients with PH (including 123 with pulmonary arterial hypertension, 47 with chronic thromboembolic PH, and 41 with other types of PH) experienced COVID-19, and 40.3% of them were outpatients, 32.2% were hospitalized in a conventional ward, and 27.5% were in an ICU. Among hospitalized patients (n = 126), 54.0% received corticosteroids, 37.3% high-flow oxygen, and 11.1% invasive ventilation. Right ventricular and acute renal failure occurred in 30.2% and 19.8% of patients, respectively. Fifty-two patients (all hospitalized) died from COVID-19. Overall mortality was 24.6% (95% CI [confidence interval], 18.8-30.5) and in-hospital mortality 41.3% (95% CI, 32.7-49.9). Nonsurvivors were significantly older, more frequently male and suffering comorbidities (diabetes, chronic respiratory diseases, systemic hypertension, chronic cardiac diseases, and/or chronic renal failure), and had more severe PH at their most recent evaluation preceding COVID-19 diagnosis (in terms of functional class and 6-minute-walk distance; all P < 0.05). Use of pulmonary arterial hypertension therapy was similar between survivors and nonsurvivors. Conclusions: COVID-19 in patients with precapillary PH was associated with a high in-hospital mortality. The typical risk factors for severe COVID-19 and severity of PH were associated with mortality in this population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a outcomes | |
| 650 | 4 | |a pulmonary arterial hypertension | |
| 650 | 4 | |a pulmonary hypertension | |
| 700 | 1 | |a Certain, Marie-Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Weatherald, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Jaïs, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Bulifon, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Noel-Savina, Elise |e verfasserin |4 aut | |
| 700 | 1 | |a Nieves, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Renard, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Traclet, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Bouvaist, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Riou, Marianne |e verfasserin |4 aut | |
| 700 | 1 | |a de Groote, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Moceri, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoletti, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Favrolt, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Guillaumot, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Jutant, Etienne-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Beurnier, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Boucly, Athénaïs |e verfasserin |4 aut | |
| 700 | 1 | |a Ebstein, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Jevnikar, Mitja |e verfasserin |4 aut | |
| 700 | 1 | |a Pichon, Jérémie |e verfasserin |4 aut | |
| 700 | 1 | |a Keddache, Sophia |e verfasserin |4 aut | |
| 700 | 1 | |a Preda, Mariana |e verfasserin |4 aut | |
| 700 | 1 | |a Roche, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Solinas, Sabina |e verfasserin |4 aut | |
| 700 | 1 | |a Seferian, Andrei |e verfasserin |4 aut | |
| 700 | 1 | |a Reynaud-Gaubert, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Cottin, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Savale, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Humbert, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Sitbon, Olivier |e verfasserin |4 aut | |
| 700 | 0 | |a French PH Network PULMOTENSION Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Kais, Ahmad |e investigator |4 oth | |
| 700 | 1 | |a Elise, Artaud-Macari |e investigator |4 oth | |
| 700 | 1 | |a Céline, Chabanne |e investigator |4 oth | |
| 700 | 1 | |a Ari, Chaouat |e investigator |4 oth | |
| 700 | 1 | |a surnameClaire, Dauphin |e investigator |4 oth | |
| 700 | 1 | |a Frédéric, Gagnadoux |e investigator |4 oth | |
| 700 | 1 | |a Anne, Gaudoin |e investigator |4 oth | |
| 700 | 1 | |a Sébastien, Hascoet |e investigator |4 oth | |
| 700 | 1 | |a Delphine, Horeau-Langlard |e investigator |4 oth | |
| 700 | 1 | |a Jocelyn, Inamo |e investigator |4 oth | |
| 700 | 1 | |a Bouchra, Lamia |e investigator |4 oth | |
| 700 | 1 | |a Pascal, Magro |e investigator |4 oth | |
| 700 | 1 | |a Jean-Claude, Meurice |e investigator |4 oth | |
| 700 | 1 | |a Patrice, Poubeau |e investigator |4 oth | |
| 700 | 1 | |a Grégoire, Prevot |e investigator |4 oth | |
| 700 | 1 | |a Roger, Rosario |e investigator |4 oth | |
| 700 | 1 | |a Servettaz |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of respiratory and critical care medicine |d 1994 |g 206(2022), 5 vom: 01. Sept., Seite 573-583 |w (DE-627)NLM074657305 |x 1535-4970 |7 nnns |
| 773 | 1 | 8 | |g volume:206 |g year:2022 |g number:5 |g day:01 |g month:09 |g pages:573-583 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1164/rccm.202112-2761OC |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 206 |j 2022 |e 5 |b 01 |c 09 |h 573-583 | ||